0611/26SCR019-18/R6RGB
Media Highlights
From the 2026 ASCO® Annual Meeting
4
Continued ➔
Media Outlet Date Article / Coverage
AJMC 5/30/26 Lee Shares Early Data on Linvoseltamab in R/R AL
Amyloidosis, Calls Responses "Unprecedented"
Cancer Network 6/1/26 Linvoseltamab May Improve Outcomes Vs Teclistamab in
R/R Multiple Myeloma
Healio 5/29/26 Linvoseltamab Data In AL Amyloidosis Could Have
'Tremendous Implications'
MedCity News 5/31/26 Regeneron Cancer Drug Shows New Promise in a Rare
Disease… and Maybe More
Pharma Journalist 5/21/26 Regeneron Reports Promising Amyloidosis Trial Results
Pharmaphorum 6/1/26 ASCO26: Could AL Amyloidosis See a New Crop of Therapies?
Soho Insider 6/4/26 Dr. Hans Lee on MRNA-2808 in Relapsed or Refractory
Multiple Myeloma
VJHemOnc 6/1/26 First Results of LINKER-AL2: Linvoseltamab in Patients With
R/R Systemic AL Amyloidosis
VJHemOnc 6/2/26 A Phase I/II Study of mRNA-2808, a Multiplexed T-cell
Engager, in Patients With R/R Multiple Myeloma
VUMEDI 6/11/26 ASCO® 2026 Insights: Linvoseltamab in Patients with R/R
Systemic Light Chain (AL) Amyloidosis - First Results From
the Ph1/2 LINKER-AL2 Trial
Hans Lee, MD
SCRI
Media Outlet Date Article / Coverage
Targeted Oncology 6/2/26 Targeting the IL-2 Pathway to Overcome Immunotherapy
Resistance in Melanoma
Meredith McKean, MD, MPH
SCRI
